Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53

Figure 6

The effect of ALDH2 inhibitor in the sensitivity to oxaliplatin on CRC cells. HT29 (p53mutant) and HCT116 (p53 wild type) cells were incubated with different doses of oxaliplatin (0-2.5 μM) with different doses of daidzein (0-100 μM). The cell viability was determined by SRB assay. In HT29 cells, cotreatment with daidzein will decrease the sensitivity to oxaliplatin treatment. There is no difference in HCT116 cells. All the experiments were performed at least three times independent. value < 0.01.